Pharmaceutical - Vanda Pharmaceuticals

Filter

Current filters:

Vanda Pharmaceuticals

Popular Filters

Positive FDA panel recommendation for Vanda’s tasimelteon

Positive FDA panel recommendation for Vanda’s tasimelteon

15-11-2013

The US Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee…

HetliozNorth AmericaOphthalmicsPharmaceuticalRegulationtasimelteonVanda Pharmaceuticals

Vanda Pharma pulls EU application for schizophrenia drug candidate Fanaptum

15-03-2013

The European Medicines Agency has been formally notified by USA-based Vanda Pharmaceuticals (Nasdaq:…

EuropeFanaptumNeurologicalPharmaceuticalRegulationVanda Pharmaceuticals

Vanda's tasimelteon meets primary endpoint in Ph III study

18-12-2012

Shares of USA-based Vanda Pharmaceuticals (Nasdaq: VNDA) moved 2.8% higher to $3.22 in early trading…

NeurologicalPharmaceuticalResearchtasimelteonVanda Pharmaceuticals

Makers of Kynamro and Fanaptum to appeal negative CHMP opinions

17-12-2012

French drug major Sanofi's (Euronext: SAN) subsidiary Genzyme and US partner Isis Pharmaceuticals (Nasdaq:…

BiotechnologyEuropeFanaptFanaptumGenzymeIsis PharmaceuticalsKynamroNeurologicalPharmaceuticalRare diseasesRegulationSanofiVanda Pharmaceuticals

Vanda gains rights to Lilly's NK-1 receptor antagonist

17-04-2012

USA-based Vanda Pharmaceuticals (Nasdaq: VNDA) said yesterday that it has acquired an exclusive worldwide…

Eli LillyLicensingNeurologicalPharmaceuticalVanda Pharmaceuticals

Mochida diabetes deal with Merck; Vanda links with Megapharm

14-12-2011

Japanese mid-sized drugmaker Mochida Pharmaceutical (TYO: 4534) saw its shares jump 5.8% to 900 yen,…

BiotechnologyDiabetesFanaptLicensingMegapharmMerck & CoMochida PharmaceuticalNeurologicalPharmaceuticalVanda Pharmaceuticals

Back to top